Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 961-972

  Senabre Gallego, José Miguel ^a   Santos Ramírez, Carlos ^b   Santos Soler, Gregorio ^a   Salas Heredia, Esteban ^a   Sánchez Barrioluengo, Mabel ^c   Barber, Xavier ^d   Rosas, José ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

^b Hospital Marina Salud   (Spain)

^c UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Ankylosing spondylitis; Efficacy; Etanercept; Safety; Spondyloarthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN G1; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE MARROW EDEMA; BREAST FEEDING; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FERTILITY; GERIATRIC PATIENT; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; MORNING STIFFNESS; NON MELANOMA SKIN CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHOTOTHERAPY; POSTPRIMARY TUBERCULOSIS; PREGNANCY; PSORIASIS; QUALITY OF LIFE; RASH; RELAPSE; REMISSION; REVIEW; RHINITIS; SACROILIITIS; SARCOIDOSIS; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VIRUS REACTIVATION; WORK DISABILITY;

EID: 84884719069     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S33109     Document Type: Review

References (100)

1. Carmona-Ortells L, Loza-Santamaría E; grupo ESPOGUIA. Management of spondyloarthritis (ESPOGUIA): methodology and general data from the document. Reumatol Clin. 2010;6 Suppl 1:1-5.
2. Hukuda S, Minami M, Saito T, etal. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554-559.
3. van der Heijde D, Landewé R, Einstein S, etal. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324-1331.
4. van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905-908.
5. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondilytis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
6. Calin A, Garrett S, Whitelock H, etal. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-2285.
7. Jenkinson TR, Mallorie PA, Whitelock H, Kennedy LG, Garrett S, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol. 1994;21:1694-1698.
8. Anderson JJ, Baron G, Van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876-1886.
9. van der Heijde D, Lie E, Kvien TK, etal. ASDAS, a highly discriminatory ASAS endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811-1818.
10. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346: 1349-1356.
11. Davis JC, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum. 2004;52:302-304.
12. Brandt J, Khariouzov A, Listing J, etal. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48: 1667-1675.
13. Brandt J, Listing J, Haibel H, etal. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005;44:342-348.
14. Davis JC, van der Heijde D, Braun J, etal. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2003;48:3230-3236.
15. Davis JC, van der Heijde D, Braun J, etal. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346-352.
16. Calin A, Dijkmans BA, Emery P, etal. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004;63:1594-600.
17. Dijkmans BAC, Emery P, Hakala M, etal. Etanercept in the long-term treatment of patients with ankylosing spondylitis. J Rheumatol. 2009;36: 1256-1264.
18. van der Heijde D, Da Silva JC, Dougados M, etal. Etanercept 50mg once weekly is as effective as 25mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572-1577.
19. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly. Rheumatology (Oxford). 2007;46:999-1004.
20. Braun J, van der Horst-Bruinsma IE, Huang F, etal. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63: 1543-1551.
21. Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23: 497-506.
22. McLeod C, Bagust A, Boland A, etal. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1-158, iii-iv.
23. Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009-a retrospective analysis. Int J Clin Pharmacol Ther. 2012;50: 867-872.
24. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69: 2002-2008.
25. Heiberg MS, Koldingsnes W, Mikkelsen K, etal. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;15;59:234-240.
26. Pavelka K, Forejtová S, Stolfa J, etal. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27:958-963.
27. Coates LC, Cawkwell LS, Ng NW, etal. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897-900.
28. Conti F, Ceccarelli F, Marocchi E, etal. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393-1397.
29. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol. 2005;32:2183-2185.
30. Rudwaleit M, van der Heijde D, Landewé R, etal. The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:77-83.
31. Haibel H, Rudwaleit M, Listing J, etal. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981-1991.
32. Barkham N, Keen HI, Coates LC, etal. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60: 946-954.
33. Song IH, Hermann K, Haibel H, etal. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomized controlled trial. Ann Rheum Dis. 2011;70:590-596.
34. Dougados M, van der Heijde D, Sieper J, etal. Clinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trial. Abstract OP0108 presented at the European League Against Rheumatism Annual Congress, Madrid, Spain, June 12-15, 2013.
35. Dougados M, Braun J, Szanto S, etal. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70:799-804.
36. Dougados M, Braun J, Szanto S, etal. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford). 2012;51:1687-1696.
37. Leonardi CL, Powers JL, Matheson RT, etal; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
38. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis; a randomised trial. Lancet. 2000;356:385-390.
39. Mease PJ, Kivitz AJ, Burch FX, etal. Etanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272.
40. Sandborn WJ, Hanauer SB, Katz S, etal. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
41. Braun J, Pavelka K, Ramos-Remus C, etal. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012;39:836-840.
42. Wang D, Ma L, Wu D. Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine. 2011;78:531-532.
43. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum. 2005;52:1216-1223.
44. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis. 2005;64:1305-1310.
45. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64:127-129.
46. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. March 27, 2013. [Epub ahead of print.]
47. van der Heijde D, Salonen D, Weissman BN, etal. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.
48. Navarro-Sarabia F, Fernández-Sueiro JL, Torre-Alonso JC, etal. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011;50:1828-1837.
49. Lee SH, Lee YA, Hong SJ, Yang HI. Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol. 2008;27:179-181.
50. Song IH, Althoff CE, Haibel H, etal. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71:1212-1215.
51. Lee J, Noh JW, Hwang JW, etal. Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29:1149-1154.
52. Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics. 2013;7:1-6.
53. Navarro-Compán V, Moreira V, Ariza-Ariza R, Hernández-Cruz B, Vargas-Lebrón C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30:993-996.
54. Cui Y, Xiao Z, Shuxia W, etal. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis. Scand J Rheumatol. 2009;27:958-963.
55. Barkham N, Coates LC, Keen H, etal. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69:1926-1928.
56. Moots RJ, Ostor AJ, Loft AG, etal. Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries. Rheumatology (Oxford). 2012;51:393-396.
57. van der Burg LR, Ter Wee MM, Boonen A. Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. Ann Rheum Dis. 2012;71:1924-1933.
58. Furst DE, Wallis R. Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of acting may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159-167.
59. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
60. Machado MA, Barbosa MM, Almeida AM, etal. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. May 18, 2013. [Epub ahead of print.]
61. Martín-Mola E, Sieper J, Leirisalo-Repo M, etal. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with AS. Clin Exp Rheumatol. 2010;28: 238-245.
62. Carmona L, Gómez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.
63. Senabre-Gallego JM, Rosas-Gómez de Salazar J, Santos-Soler G, et al. Duration of treatment with etanercept and motives for discontinuation in a cohort of patients with rheumatic disease. Reumatol Clin. 2011;7: 385-388.
64. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790.
65. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum. 2008;37:251-255.
66. Santos-Ramírez C, Rosas J, Senabre JM, etal. Es necesario repetir la prueba de tuberculina en los pacientes en tratamiento biológico? Resultados preliminares en una cohorte local de pacientes con artropatía inflamatoria. [Is it necessary to repeat the tuberculin test in patients on biological treatment? Preliminary results on a local cohort of patients with inflammatory arthropathy.] Rev Sociedad Val Reuma. 2011;2:15-16. Spanish.
67. Tubach F, Salmon D, Ravaud P, etal. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-1894.
68. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69: 522-528.
69. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009;36:914-917.
70. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis. 2003;62:561-564.
71. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. 2003;48:780-790.
72. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNF alpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710-713.
73. Bacquet-Deschryver H, Jouen F, Quillard M, etal. Impact of three anti-TNF alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol. 2008;28:445-455.
74. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700-1711.
75. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710-712.
76. Lee ES, Heller MM, Kamangar F, Park KK, Koo JY. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. J Drugs Dermatol. 2012;11:413-414.
77. De Vries MK, Van Der Horst-Bruinsma IE, Nurmohamed M, etal. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (AS). Ann Rheum Dis. 2009;68: 531-535.
78. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21:211-215.
79. Jamnitski A, Krieckaert CL, Nurmohamed MT, etal. Patients nonresponding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71:88-91.
80. Daïen CI, Daïen V, Parussini E. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol. 2012;39:1533-1538.
81. Dore RK, Mathews S, Schechtman J, etal. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:40-46.
82. Fiorentino DF. The yin and yang of TNF-alpha inhibition. Arch Dermatol. 2007;143:233-236.
83. Furst DE, Keystone EC, Kirkham B, etal. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008;67 Suppl 3:iii2-iii25.
84. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010;37:2205-2215.
85. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients withrheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol. 2012;30:756-764.
86. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248-3252.
87. Javot L, Tala S, Scala-Bertola J, etal. Sarcoidosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review. Therapie. 2011;66:149-154. French.
88. Pato E, Muñoz-Fernández S, Francisco F, etal. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40:314-323.
89. D'Angelo S, Palazzi C, Cantini F, Lubrano E, Marchesoni A, Mathieu A. Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol. 2011;29:865-870.
90. Mrabet D, Selmi A, Filali A, Sahli H, Sellami S. Onset of Crohn's disease induced by etanercept therapy: a case report. Rev Med Liege. 2012;67:619-622. French.
91. González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817-820.
92. Lamrock E, Brown P. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol. 2012;53:e87-e90.
93. Fleischmann R, Iqbal I. Risk:benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24:239-254.
94. Scioscia C, Scioscia M, Anelli MG, Praino E, Bettocchi S, Lapadula G. Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis. Clin Exp Rheumatol. 2011;29: 93-95.
95. Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382-390.
96. Østensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47 Suppl 3:iii28-iii31.
97. Rump JA, Schönborn H. Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z Rheumatol. 2010;69:903-909.
98. Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:395-399.
99. Said TM, Agarwal A, Falcone T, Sharma RK, Bedaiwy MA, Li L. Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril. 2005;83:1665-1673.
100. Borrego L. Etanercept in pregnancy and breast-feeding. Actas Dermosifiliogr. 2010;101 Suppl 1:97-101.